英文互译镜像站

List of investigational eating disorder drugs

Last updated January 29, 2026

This is a list of investigational eating disorder drugs, or drugs that are currently under development for clinical use for the treatment of eating disorders but are not yet approved. Eating disorders include anorexia nervosa, bulimia nervosa, and binge-eating disorder, among others. This page does not include drugs under development for treatment of overweightness/obesity (excessive appetite) or anorexia (low appetite).

Under development

Phase 3

Armodafinil ((R)-modafinil; CEP-10953; Nuvigil) – atypical dopamine reuptake inhibitor (DRI) – eating disorders
Solriamfetol (ADX-N05; ARL-N05; JZP-110; SKL-N05; Sunosi) – norepinephrine–dopamine reuptake inhibitor (NDRI) – binge-eating disorder

Phase 2

BP-14979 (BP-1.4979; BP1-4979) – dopamine D₃ receptor partial agonist – binge-eating disorder
Lidocaine (ORE-001) – sodium channel blocker – anorexia nervosa
Naloxone nasal spray (LT-12; LT-20; LT-21; LT-22; Naloxon B; Narcan nasal spray; OPNT-001) – μ-opioid receptor antagonist – eating disorders
Nivasorexant (ACT-539313; SORA) – orexin OX₁ receptor antagonist – binge-eating disorder
Oxytocin (intranasal potentiated oxytocin; TI-001; TI-114; TNX-1900; TNX-2900) – oxytocin receptor agonist – binge-eating disorder
Psilocybin (COMP-360; COMP360) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, and serotonergic psychedelic – anorexia nervosa
Psilocybin (PFN™; TRP-8802; TRP-8803; TRP-8804; TRYP-0082) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, and serotonergic psychedelic – binge-eating disorder
Vortioxetine (Brintellix; LU-AA21004; LuAA 21004; Trintellix; Vortidif) – serotonin reuptake inhibitor, serotonin 5-HT_1A and 5-HT_1B receptor agonist, and serotonin 5-HT_1D, 5-HT₃, and 5-HT₇ receptor antagonist – binge-eating disorder

Phase 1

CVN-766 (CVN766) – orexin OX₁ receptor antagonist – binge-eating disorder

Preclinical

Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor and cortisol synthesis inhibitor) and oxazepam (benzodiazepine/GABA_A receptor positive allosteric modulator) – eating disorders

Not under development

No development reported

BMB-101 (BMB101) – serotonin 5-HT_2C receptor agonist – binge-eating disorder
GSK-598809 (GSK598809) – dopamine D₃ receptor antagonist – eating disorders
Ketamine (AWKN-001; AWKN-P-001) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – binge-eating disorder
Olanzapine (BR-5402; LY-170053; LY-170052; Midax; Zypadhera; Zyprexa) – atypical antipsychotic (non-selective monoamine receptor modulator) – anorexia nervosa

Discontinued

Amphetamine modified release (HLD-900; HLD-100) – norepinephrine–dopamine releasing agent (NDRA) – bulimia nervosa
Centanafadine (CTN-SR; EB-1020) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – binge-eating disorder
Dasotraline (DSP-225289; SEP-225289; SEP-0225289; SEP-289) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – binge-eating disorder
Femoxetine (femoxitine; FG-4963; Malexil; NNC-204963) – selective serotonin reuptake inhibitor (SSRI) – eating disorders
Ghrelin synthetic (OXE-103; SUN-11031) – ghrelin receptor agonist – anorexia nervosa
GW-181771 (GI-181771; GSKI-181771X) – cholecystokinin CCK_A receptor agonist – bulimia nervosa
Meclinertant (reminertant; SR-48692) – neurotensin NTS₁ receptor antagonist – anorexia nervosa
Naloxone nasal spray (LT-12; LT-20; LT-21; LT-22; Naloxon B; Narcan nasal spray; OPNT-001) – μ-opioid receptor antagonist – bulimia nervosa
Samidorphan (ALKS-33; RDC-0313; RDC-0313-00) – μ-opioid receptor antagonist – eating disorders
Sertraline (Aremis; Besitran; CP-51974; CP-51974-01; Gladem; J Zoloft; Lustral; Serad; Serlain; Tatig; Zoloft) – selective serotonin reuptake inhibitor (SSRI) – night eating syndrome
Tandospirone (metanopirone; Sediel; SM-3997) – serotonin 5-HT_1A receptor agonist – eating disorders
Ticalopride ((+)-norcisapride) – serotonin 5-HT₃ receptor antagonist, serotonin 5-HT₄ receptor agonist – bulimia nervosa

Clinically used drugs

Approved drugs

Dronabinol (tetrahydrocannabinol; THC; Δ₉-THC; Deltanyne; Elevat; Marinol; NSC-134454) – cannabinoid CB₁ and CB₂ receptor agonist – anorexia nervosa
Fluoxetine (LY-110140; Prozac; Reneuron; Sarafem) – selective serotonin reuptake inhibitor (SSRI) – bulimia nervosa
Fluoxetine – selective serotonin reuptake inhibitor (SSRI) – bulimia nervosa
Lisdexamfetamine (LDX; Elvanse; NRP-104; S-877489; SHP-489; SPD-489; Tyvense; Venvanse; Vyvanse) – norepinephrine–dopamine releasing agent (NDRA) – eating disorders

References

External links

AdisInsight - Springer

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

镜像精灵烟雨镜像程序蚂蚁超级镜像站群克隆软件 MirrorElfR